INmune Bio (Nasdaq: INMB) is developing therapies that harness patient’s immune system to treat disease. Our focus is on #cancer, #Alzheimer’s disease.
Joined October 2016
- Tweets 1,740
- Following 4,902
- Followers 4,942
- Likes 1,543
875 Photos and videos
Pinned Tweet
Feb 12
$INMB announced FDA alignment on an integrated Phase 2b/3 registration pathway for #XPro1595 in early #alzheimers.
The FDA raised no objection to the development strategy and confirmed CDR-SB as the sole primary endpoint.
Full PR: bit.ly/3MG165k
#RegulatoryMilestone
1
9
966
Feb 26
As #RareDiseaseMonth comes to a close, #INmuneBio recognizes the millions affected by #raredisease and the ongoing need for innovation.
$INMB is advancing novel therapies for high unmet need conditions like #RDEB, a rare genetic disease with systemic impact beyond the skin.
ALT Graphic recognizing Rare Disease Month in February, featuring overlapping human silhouettes, a white awareness ribbon, and the INmune Bio logo, representing rare genetic diseases, RDEB, and biotech research.
1
6
546
Feb 24
On the @Xtalks Life Science Podcast, $INMB CEO David Moss discusses #INmuneBio’s dominant-negative inhibitor platform targeting chronic inflammation.
From #RDEB to #Alzheimers, learn how innate immunity may reshape treatment.
Listen on @YouTube: bit.ly/4aqNHWR
1
3
513
Feb 19
February 14-21 is Alzheimer’s & Dementia Care Education Week, highlighting the role of education and innovation in care for those impacted by #Alzheimers.
With support from the @alzassociation, $INMB is advancing therapies targeting the underlying drivers of Alzheimer’s disease.
ALT Graphic highlighting Alzheimer’s & Dementia Care Education Week, February 14-21, featuring a purple brain illustration, blue headline text, and the INmune Bio logo in the bottom corner.
1
6
597
Feb 17
$INMB CEO & Co-Founder David Moss discusses INmune Bio’s precision immune modulation approach in Drug Discovery Online, highlighting the #CORDStrom and #XPro programs targeting harmful inflammation across rare and neurodegenerative diseases.
Read more: bit.ly/4rCt7K2
1
8
749
Feb 10
#INmuneBio advances #CORDStrom for #RDEB with a key regulatory milestone.
$INMB has submitted its pre-submission package to the UK MHRA to streamline approval and shorten time-to-market.
Full PR: bit.ly/4aq1b5d
#RareDisease #RegulatoryMilestone #INMB
2
8
738
#WorldCancerDay underscores the need for smarter, more precise approaches to disease.
#INmuneBio studies the innate immune system and how restoring immune balance may support new approaches to #cancer and other serious diseases.
$INMB #CancerResearch #Biotech
ALT World Cancer Day awareness graphic for INmune Bio featuring a blue background with a light-colored world map and a large blue cancer awareness ribbon centered over the map. Text at the bottom reads “World Cancer Day, Wednesday, 4 February,” with the INmune Bio Innate Immunity logo in the upper right corner.
8
230
Recessive Dystrophic Epidermolysis Bullosa (#RDEB) is a rare genetic condition causing fragile skin, blisters, & challenges with eating, swallowing, joints, hair, & more.
$INMB is advancing research to improve the lives of those affected.
Learn more: bit.ly/47aLA7I
ALT Awareness graphic for INmune Bio highlighting Recessive Dystrophic Epidermolysis Bullosa (RDEB). The graphic displays the condition name prominently along with a section titled “Main Symptoms,” listing skin blisters and scarring, swallowing difficulties, and joint and hair problems. The INmune Bio Innate Immunity logo appears at the top, with a grayscale image of a child’s hand being gently held by an adult on the right side.
7
487
Jan 29
Today we’re spotlighting Mark Lowdell, CSO & CMO of #INmuneBio.
Serving in this role since 2015, Mark brings decades of leadership in translational #immunotherapy and cell-based medicine.
Learn more: bit.ly/4mRR9hk
$INMB #EmployeeSpotlight
6
465
Jan 28
#INmuneBio issued a shareholder letter reviewing 2025 milestones & outlining 2026 strategic initiatives, highlighting progress with #XPro1595 in early #Alzheimers disease & continued advancement of #CORDStrom in #RDEB.
Read more: bit.ly/4bitRPD
$INMB #ShareholderUpdate
7
291
Jan 27
In a recent Rare Connection podcast, Mark Lowdell, CSO & Co-Founder of $INMB, discusses #CORDStrom, an investigational cell therapy for #RDEB.
The conversation highlights clinical progress, the regulatory path ahead, & patient impact.
Listen on @Spotify: bit.ly/4qkdma8
6
394
Jan 22
CEO David Moss shares his perspective on the #pharma advances that have shaped the industry over the past 30 years in a @pharmasalmanac roundtable, from biologics to advanced antibody engineering.
Full roundtable featuring industry leaders:
bit.ly/3LnQzen
$INMB
7
496
Jan 20
Spotlighting Cory Ellspermann, Interim CFO at #INmuneBio.
With nearly 30 years of financial leadership, Cory has been instrumental in strengthening $INMB's financial operations since joining in 2019.
Proud to highlight his #leadership.
Learn more: bit.ly/4mRR9hk
6
499
Jan 15
In a new expert discussion from @ClinicalLeader1, researchers call for a shift beyond legacy clinical trial design.
David Moss, CEO and co-founder of $INMB, shares why #biology-driven endpoints and enrolling the right patients matter.
Full POV: bit.ly/3YvyqhT
8
509
Jan 13
$INMB is advancing therapies for RDEB, a #raredisease affecting skin, causing pain, wounds, & systemic issues.
Groups like @debraOfAmerica & @EBResearch support the #RDEB community, working toward better treatments and brighter futures.
Learn more: bit.ly/4q2oM2Q
7
657
#INmune's CEO, David Moss, joins industry leaders in @pharmasalmanac's roundtable on how capital constraints are reshaping M&A and partnerships across pharma and CDMOs.
Read the full roundtable: bit.ly/4aI2spW
#INMB #PharmaTrends #Biotech
6
279
$INMB CEO David Moss spoke with @timsandle of @digitaljournal on late-stage programs targeting immune dysfunction & chronic inflammation.
He shares updates on CORDStrom for #epidermolysisbullosa, XPro for #Alzheimers, and upcoming milestones.
Read more: bit.ly/4b3b4Ya
1
1
7
828
23 Dec 2025
Happy Holidays from #INmuneBio!
Wishing you a joyful season and a healthy, successful year ahead.
#INMB #HappyHolidays
7
367
18 Dec 2025
Featuring Tara Lehner, Vice President of Clinical Operations at #INmuneBio.
Tara has 22 years of experience across pharma, biotech, and CROs, and previously managed a $400 million strategic partnership portfolio.
Learn more about the $IMNB team: bit.ly/4mRR9hk
8
254
16 Dec 2025
#INmuneBio highlights #XPro & its potential to transform care for those affected by #Alzheimers.
Hear from $INMB's CEO on the progress following the Phase 2 trial& next steps in a recent #NanoCapPodcast.
Full episode: bit.ly/4o3sckk
8
359